If nucleotide and amino acid sequences corresponding to the definition in WIPO Standard ST.25, paragraph 2(ii), are disclosed in the European patent application, they should be represented in a sequence listing which conforms to this WIPO Standard. The sequence listing should preferably be filed as part of the description, although it may also be filed later, in which case it does not form part of the application. In addition to submission in written form on paper or electronically, the sequence listing must also be submitted in computer readable form either on an authorised electronic data carrier or as attached to the electronically filed application. Data in computer readable form must comply with WIPO Standard ST. 25, paragraph 39ff. The information recorded on the electronic data carrier must be identical to the written sequence listing which is the authentic version. The applicant or his representative must submit a statement to that effect accompanying the data carrier in accordance with Rule 27a(2). See the Decision of the President of the EPO dated 2 October 1998 and the accompanying Notice from the EPO, Supplement No. 2 to OJ 11/1998.

The Receiving Section will inform the applicant of any deficiencies in the written sequence listing, the electronic data carrier or the statement under Rule 27a(2) and invite him to remedy the deficiencies within a period of two months. If the requirements of Rule 27a in conjunction with the Decision of the President of the EPO dated 2 October 1998 are not complied with in good time, where appropriate following the invitation to do so from the Receiving Section, the application will be refused.

The applicant may request further processing of the application.